SCHEMBL18464633

SCHEMBL18464633

CC(C)(C)c1ccc(-c2c(CBr)ncc3ccccc23)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR84 Q9NQS5 1/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ TNKS O95271 1/20 0.37
▸ TNKS2 Q9H2K2 1/20 0.37
▸ CCR4 P51679 1/20 0.36
▸ KIF11 P52732 2/20 0.36
▸ NPC1 O15118 3/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ TRPM8 Q7Z2W7 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ TNF P01375 1/20 0.35
▸ NOD1 Q9Y239 1/20 0.35
▸ LMNA P02545 2/20 0.35
▸ NR1I2 O75469 1/20 0.35
▸ ADRA2A P08913 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ ACHE P22303 1/20 0.35
▸ SLC6A2 P23975 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18464728 0.86 TACR1 (0.39) TNKSTNKS2KIF11MAPTTRPV1
SCHEMBL18426863 0.86 GPR84 (0.39) GPR84SMN1; SMN2TP53TNKSTNKS2
SCHEMBL18425737 0.86 GPR84 (0.44) GPR84SMN1; SMN2TP53TNKSTNKS2
SCHEMBL18464716 0.81 CYP1A2 (0.43) GPR84SMN1; SMN2TNKSTNKS2KMT2A
SCHEMBL18464722 0.78 EGFR (0.40) MEN1KMT2AAKT1
SCHEMBL18425832 0.76 DHODH (0.40) KDM4EMAPTHTTNPSR1AKT1
SCHEMBL18464720 0.76 CYP11B1 (0.37) NPC1LMNAKDM4EMAPTHTT
SCHEMBL18464723 0.74 TDP1 (0.48) KDM4EHTTNPSR1GPR3
SCHEMBL18425748 0.74 PIK3CD (0.37) TRPM8TNFKCNH2KDM4EGPR3
SCHEMBL18464729 0.73 CHEK1 (0.37) KDM4EGPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3328859-B1 3-((4-ISOQUINOLIN-3-YL)METHYL)-1H-IMIDAZO[4,5-C]PYRIDIN-2(3H)-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) BOEHRINGER INGELHEIM INT (DE) 2020-06-03 — — EP disclosed
US-20190002436-A1 RESPIRATORY SYNCYTIAL VIRUS INHIBITORS MEDIVIR AB (SE) 2019-01-03 — — US disclosed
WO-2017018924-A1 RESPIRATORY SYNCYTIAL VIRUS INHIBITORS MEDIVIR AB (SE) 2017-02-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190002436-A1 RESPIRATORY SYNCYTIAL VIRUS INHIBITORS NR0B1, NR1I3, SCARB1 GPR84 394/4885SMN1; SMN2 868/4885TP53 4513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback